Canada markets closed

Deltron, Inc. (DTRO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.00300.0000 (0.00%)
At close: 11:54AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0030
Open0.0030
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0030 - 0.0030
52 Week Range0.0001 - 0.0045
Volume200
Avg. Volume1,721
Market Cap100,922
Beta (5Y Monthly)-0.46
PE Ratio (TTM)N/A
EPS (TTM)-7.2270
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI
    Business Wire

    Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI

    Gilead Sciences, Inc. (Nasdaq: GILD) today presented additional results from the Phase 2/3 CAPELLA trial evaluating the company’s investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, in heavily treatment-experienced people with multi-drug resistant HIV-1 infection. The data build on the positive primary endpoint results announced previously. The new interim efficacy results demonstrate that lenacapavir administered subcutaneously every six months maintained high rates of virologic suppression through 26 weeks in a difficult-to-treat patient population with limited therapy options and high unmet medical need. In this analysis of the ongoing maintenance period of CAPELLA, which evaluated lenacapavir in combination with an optimized background regimen, 73% (n=19/26) of participants who reached Week 26 since the first dose of subcutaneous lenacapavir achieved undetectable viral load (<50 copies/mL). The data were presented at the 28th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2021).

  • Yahoo Finance Video

    Fmr. White House Doctor: It’s ‘ill advised’ to relax COVID-19 mandates amid spreading variants

    Dr. Jennifer Pena, Nurx Chief Medical Officer & Former White House Medical Unit Physician for Obama, Biden and Pence, joins Yahoo Finance’s Julie Hyman and Alexis Christoforous to discuss the latest coronavirus updates and women in medicine.

  • Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI
    Business Wire

    Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI

    Gilead Sciences, Inc. (Nasdaq: GILD) today announced new, long-term data from open-label extensions (OLE) of two Phase 3 studies (Study 1489 and Study 1490) of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF), demonstrating the sustained efficacy and safety profile and no treatment-emergent resistance with Biktarvy for the treatment of HIV-1 in treatment-naïve adults. The data were presented at the 28th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2021).